GAITHERSBURG, Md., Jan. 6, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (the "Company" or "Cytomedix"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that it will amend and restate its financial results for the year 2009, as well as its results for each of the quarters of 2009 and for the first three quarters of 2010. The adjustments will result in non-cash charges to be reflected below the loss from operations line in the Company's statements of operations, and will have no impact on the Company's cash balances or loss from operations.
